Literature DB >> 8602778

Multicenter trial of cryotherapy for retinopathy of prematurity. Snellen visual acuity and structural outcome at 5 1/2 years after randomization.

.   

Abstract

OBJECTIVE: To evaluate outcome at 5 1/2 years after randomization in eyes that underwent cryotherapy and in control eyes of patients in the Multicenter Trial of Cryotherapy for Retinopathy of Prematurity.
DESIGN: During infancy, patients with bilateral threshold retinopathy of prematurity (ROP) were assigned to receive cryotherapy for one eye and no cryotherapy for the other eye. Those with threshold ROP in only one eye (asymmetric) were randomly assigned to cryotherapy or no cryotherapy for that eye. Then, 5 1/2 years later, testers who were masked to the treatment status of each eye measured the patients' monocular visual acuity by using the log of the minimum angle of resolution visual acuity chart that was used in the Early Treatment of Diabetic Retinopathy Study. This was the most refined visual acuity testing yet performed on this cohort. Structural outcome was evaluated by participating ophthalmologists' assessment of ROP residua in the posterior pole of the fundus. PATIENTS: Patients were 291 children who had been preterm infants with birth weights of less than 1251 g in whom threshold ROP had developed. Two hundred forty patients had bilateral threshold ROP, and 51 had threshold ROP in only one eye.
RESULTS: For the 234 children examined, both visual acuity and fundus structure showed a reduction in unfavorable outcomes in treated vs control eyes: 47.1% vs 61.7%, respectively (P<.005), for visual acuity and 26.9% vs 45.4%, respectively (P<.001), for fundus status. Detailed analysis of visual acuity outcomes for all eyes revealed that while fewer treated eyes (31.5%) than control eyes (48%) were blind (P<.001), there was a slight trend toward fewer eyes with a visual acuity of 20/40 or better in the treated (13%) vs control (17%) groups (P=.19).
CONCLUSIONS: The results support the long-term efficacy and safety of cryotherapy in the treatment of severe ROP. However, the data show preliminary evidence of a possible adverse effect of this treatment on visual acuity.

Entities:  

Mesh:

Year:  1996        PMID: 8602778     DOI: 10.1001/archopht.1996.01100130413008

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  41 in total

Review 1.  The management of retinopathy of prematurity.

Authors:  J D Reynolds
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

2.  Screening for retinopathy of prematurity.

Authors:  L Andruscavage; D J Weissgold
Journal:  Br J Ophthalmol       Date:  2002-10       Impact factor: 4.638

3.  Retinal features predictive of progressive stage 4 retinopathy of prematurity.

Authors:  M Elizabeth Hartnett; Janet R McColm
Journal:  Retina       Date:  2004-04       Impact factor: 4.256

4.  Variations in the morphology of retinopathy of prematurity in extremely low birthweight infants.

Authors:  W E Schulenburg; G Tsanaktsidis
Journal:  Br J Ophthalmol       Date:  2004-12       Impact factor: 4.638

5.  Estrogen therapy to treat retinopathy in newborn mice.

Authors:  Wenjing Shi; L I Zhu; Yuhuan Wang; Baoyang Hu; Honglei Xiao; Guoming Zhou; Chao Chen
Journal:  Exp Ther Med       Date:  2015-06-05       Impact factor: 2.447

6.  Fibrovascular organization in the vitreous following laser for ROP: implications for prognosis.

Authors:  M Elizabeth Hartnett; Janet R McColm
Journal:  Retina       Date:  2006-09       Impact factor: 4.256

Review 7.  [Guidelines for ophthalmological screening of premature infants].

Authors:  C Jandeck
Journal:  Ophthalmologe       Date:  2008-01       Impact factor: 1.059

8.  [Guidelines for ophthalmologic screening of premature infants].

Authors:  C Jandeck; U Kellner; B Lorenz; V Seiberth
Journal:  Ophthalmologe       Date:  2008-10       Impact factor: 1.059

Review 9.  Retinopathy of prematurity.

Authors:  Ann Hellström; Lois E H Smith; Olaf Dammann
Journal:  Lancet       Date:  2013-06-17       Impact factor: 79.321

10.  Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial.

Authors:  William V Good
Journal:  Trans Am Ophthalmol Soc       Date:  2004
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.